Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 602-611

  Adenis, A ^a   Bonneterre, J ^a   Bonneterre, M E ^a   Pion, J M ^a   Vanlemmens, L ^a   Gladieff, L ^a   De Lafontan, B ^a   Martel, P ^a   Mihura, J ^a   Roche H ^a   Gedouin D ^a   Kerbrat, P ^a   Lesimple, T ^a   Bremond A ^a   Devaux, Y ^a   Delecroix, V ^a   Fumoleau, P ^a   Maugard Louboutin, C ^a   Namer, M ^a   Goudier, M J ^a   Morice, F ^a   Montcuquet, P ^a   Schraub, S ^a   Coudert, B ^a   Fargeot, P ^a   De Gislain, C ^a   Mayer, F ^a   Bastit, P ^a   Chevallier, B ^a   Grandgirard, A ^a   Monnier, A ^a   Sun, X ^a   Clavere P ^a   Ollivier, J P ^a   Rhein, B ^a   Roullet, B ^a   Datchary, J ^a   Audhuy, B ^a   Barats, J C ^a   Kohser, F ^a   Dides, S ^a   Ramos, R ^a   Cattan, A ^a   Eymard, J C ^a   Pourny, C ^a   Weber, B ^a   De Laroche, G ^a   Pichon, A ^a   Seffert, P ^a   Hayat, M ^a   Zambon, E ^a   Chollet, P ^a   Van Praagh, I ^a   more..

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALOPECIA; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FRANCE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; VOMITING;

EID: 0035253733     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.602     Document Type: Article

References (50)

1. Adjuvant chemotherapy in stage II breast cancer, an overview of the NSABP clinical trials
2. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base
3. Development and use of a natural history data base of breast cancer study
4. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer
5. Adriamycin in breast cancer: An overview of studies
6. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy
7. Chemotherapy versus chemoimmunotherapy (CAF v CAFP v CMF each ± MER) for metastatic breast carcinoma of the breast
8. Advantage of an adriamycin plus halotestin after initial cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone for adjuvant therapy of node positive stage II breast cancer
9. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration
10. Doxorubicin-containing regimens for the treatment of stage II breast cancer. The NSABP experience
11. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive node breast cancer patients with tamoxifen non responsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
12. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes
13. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial
14. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
15. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin
16. CMF or anthracycline-based adjuvant chemotherapy for node-positive breast cancer patients: 4 year results of a Belgian randomised clinical trial with predictive markers analysis
17. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin
18. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer. An Italian multicentre trial
19. Better outcome of premenopausal node-positive breast cancer patients treated with 6 cycles vs 3 cycles of adjuvant chemotherapy: Eight year follow-up results of FASG 01
20. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial
21. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
22. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer
23. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
24. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: Findings from NSABP B-22
25. P-tests and intervals for comparison suggested by the data
26. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma
27. Nonparametric estimation from incomplete observations
28. Asymptotically efficient rank invariant test procedures
29. Regression models and life-tables
30. Polychemotherapy for early breast cancer: An overview of the randomised trials
31. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity
32. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity
33. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
34. Improved disease-free survival and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
35. A randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 for node-positive operable breast cancer early report
36. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
37. The effect of increasing dose intensity and cumulative dose of adjuvant cyclophosphamide in node positive breast cancer: Results of NSABP B-25
38. Selecting patients for higher dose adjuvant CAF: c-erbB-2, p53, dose and dose intensity in stage II, node + breast cancer (CALGB 8869 and 8541)
39. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing CAF T and tamoxifen alone
40. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
41. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
42. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer
43. Cardiac sequelae in operable breast cancer after CMF ± doxorubicin (A) ± irradiation
44. Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy
45. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience
46. b supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy
47. Adjuvant doxorubicin, vincristine, cyclophosphamide, fluorouracil (AVCF), for breast cancer: No treatment-related leukemia at 13-year follow-up
48. Acute myeloid leukemia and myelodysplastic syndrome on NSABP B-25: An update
49. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer